Physician profile
Kempaiah A Gowda
NPI 1730133265
$4,240.42
in general payments reported to CMS, 2019-2025
36 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $529 · 2021: $612 · 2022: $813 · 2023: $617 · 2024: $527 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $955.25 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $373.27 | 2019-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $327.62 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $286.66 | 2021-2024 | Verquvo |
| Medtronic Vascular, INC. | $271.69 | 2019-2020 | |
| Philips North America LLC | $245.19 | 2020-2025 | (Ck4) Mcot, (5044) Mcot, Ecc Solutions |
| Novartis Pharmaceuticals Corporation | $168.97 | 2019-2023 | |
| Boston Scientific Corporation | $149.66 | 2019-2023 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $147.25 | 2019-2023 | Farxiga, Andexxa |
| Astellas Pharma US INC | $132.00 | 2021 | |
| Amgen INC. | $108.10 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $104.21 | 2023 | Assure Wcd |
| Truvic Medical, INC. | $100.00 | 2022 | |
| Pfizer INC. | $99.95 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.09 | 2019-2023 | Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $97.15 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $65.44 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $62.06 | 2019-2021 | |
| Abbott Laboratories | $54.45 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $50.78 | 2023-2024 | Uptravi, Opsumit |
| Novo Nordisk INC | $37.11 | 2019-2025 | Wegovy |
| Veryan Medical Incorporated | $36.60 | 2022-2023 | Biomimics 3d Vascular Stent System |
| Cvrx, INC. | $28.64 | 2024 | Barostim Neo System |
| Edwards Lifesciences Corporation | $26.28 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.09 | 2022 | |
| Akcea Therapeutics, INC. | $21.78 | 2020 | |
| Impulse Dynamics (USA) INC. | $20.25 | 2022 | |
| Medtronic, INC. | $18.91 | 2022 | |
| Bardy Diagnostics, INC. | $18.77 | 2022 | |
| Esperion Therapeutics, INC. | $18.70 | 2025 | Nexletol |
| Tactile Systems Technology INC | $18.26 | 2021 | |
| Sobi, INC | $17.22 | 2021 | |
| Scpharmaceuticals INC. | $16.01 | 2024 | |
| Chiesi USA, INC. | $14.48 | 2025 | Cleviprex, Kengreal |
| Medicomp INC | $12.78 | 2019 | |
| Baxter Healthcare | $12.75 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kempaiah Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.